Major Adverse Cardiovascular Events in Angiogenesis Inhibitor‐Based Cancer Therapy: A Systematic Review and Meta‐Analysis
AIs significantly increase the risk of cardiovascular events in patients with cancer, particularly when combined with other treatments. Clinicians should balance the benefits and cardiovascular risks of AIs and consider strategies to reduce these adverse effects. Further research is needed to refine these insights.
Authors
- Hui Xu (ORCID: https://orcid.org/0000-0001-5517-3556)
- Jing Zeng (ORCID: https://orcid.org/0000-0002-4736-4210)
- Weilu Cui (ORCID: https://orcid.org/0000-0003-4762-1376)
- Haixia Li (ORCID: https://orcid.org/0009-0002-2357-2071)
- Wenyuan Song (ORCID: https://orcid.org/0009-0003-6727-4516)
- Yuxuan Tao (ORCID: https://orcid.org/0000-0001-5307-7202)
Institutions
- Guangzhou University of Chinese Medicine (CN)
- Dongguan People’s Hospital (CN)
- Guang’anmen Hospital (CN)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1161/jaha.125.042896
- Primary Topic
- Chemotherapy-induced cardiotoxicity and mitigation
- Type
- article
- Field-Weighted Citation Impact
- 0.00